| 沈婉寄,李 晖.HER2基因变异非小细胞肺癌的治疗研究进展[J].肿瘤学杂志,2022,28(10):809-817. |
| HER2基因变异非小细胞肺癌的治疗研究进展 |
| Research Progress on the Treatment of Non-small Cell Lung Cancer Harboring HER2 Alterations |
| 投稿时间：2022-08-28 |
| DOI：10.11735/j.issn.1671-170X.2022.10.B003 |
|
 |
| 中文关键词: 人表皮生长因子受体2 非小细胞肺癌 抗体偶联药物 靶向治疗 |
| 英文关键词:human epidermal growth factor receptor 2 non-small cell lung cancer antibody-drug conjugates targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 451 |
| 全文下载次数: 106 |
| 中文摘要: |
| 摘 要：目前，针对肺癌少见驱动基因突变的治疗仍是非小细胞肺癌(non-small cell lung cancer，NSCLC)治疗的热点和难点。与经典突变相比，人表皮生长因子受体2(human epidermal growth factor receptor 2，HER2)变异的NSCLC患者对传统化疗及非选择性酪氨酸激酶抑制剂(tyrosine kinase inhibitors，TKIs)反应欠佳。近年来，以新型选择性TKIs和抗体偶联药物(antibody-drug conjugates，ADCs)为代表的新兴治疗策略深刻改变了HER2变异NSCLC的治疗格局。全文对HER2变异晚期NSCLC患者的治疗进展与挑战作一综述。 |
| 英文摘要: |
| Abstract： At present，targeting rare driver variants in non-small cell lung cancer(NSCLC) remains the hotspots and challenge. Compared with canonical mutations，NSCLC patients with human epidermal growth factor receptor 2(HER2) alterations show worser response to chemotherapy and non-selective tyrosine kinase inhibitors(TKIs). The treatment landscape has dramatically changed in recent years owing to the exploring of novel therapeutic strategies represented by novel selective TKIs and antibody-drug conjugates(ADCs). This article reviews the treatment progress and challenges of advanced NSCLC patients with HER2 alterations. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |